文献速递乳腺癌

70基因特征MammaPrint在早期HR阳性HER2阴性乳腺癌高危亚组中的MINDACT试验结果

70-gene signature MammaPrint for early-stage HR-positive, HER2-negative breast cancer: Outcome in the MINDACT trial for key clinical-pathological high-risk subgroups.
PubMed 文献 · Eur J Cancer · 2026-09-11

该探索性分析纳入MINDACT试验中50岁以上、I-II期HR阳性HER2阴性、临床高危/基因组低危的868例患者,评估70基因特征在高危亚组中的预后表现。中位随访8.7年,未接受辅助化疗者8年无远处转移生存率在肿瘤>2cm、3级肿瘤及淋巴结阳性亚组分别为87.9%、91.3%和89.6%,辅助化疗绝对获益分别为1.2%、-2.2%和0.7%。结论支持70基因特征在这些高危特征患者中的预后价值。

要点

  • 50岁以上I-II期HR阳性HER2阴性临床高危/基因组低危患者可依据70基因特征评估预后。
  • 肿瘤>2cm、3级或1-3枚淋巴结阳性者未化疗8年DMFS为87.9%-91.3%。
  • 上述高危亚组中辅助化疗的8年绝对DMFS获益有限(-2.2%至1.2%)。

核心结论

  • 该MINDACT探索性亚组分析证实70基因特征在肿瘤较大、3级肿瘤及1-3枚淋巴结阳性等高危特征患者中具有预后价值。

研究设计与样本

  • MINDACT试验的探索性亚组分析,入选50岁以上、原发I-II期HR阳性HER2阴性、临床高危/基因组低危患者868例。

主要发现

  • 中位随访8.7年,490例(56.5%)肿瘤>2cm,232例(26.7%)为3级肿瘤,406例(46.8%)有1-3枚淋巴结受累。
  • 未化疗组8年DMFS:肿瘤>2cm者为87.9%(95%CI: 82.9-91.6%),3级肿瘤者为91.3%(95%CI: 84.0-95.4%),淋巴结阳性者为89.6%(95%CI: 84.2-93.3%)。
  • 辅助化疗对比未化疗的8年绝对DMFS获益分别为1.2%、-2.2%和0.7%。

临床怎么用

  • 对50岁以上I-II期HR阳性HER2阴性、临床高危但70基因特征低危的患者,可结合高危特征评估辅助化疗的必要性。

局限性

  • 本文为探索性亚组分析,结果需谨慎解读。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Adjuvant chemotherapy (ACT) can be safely omitted in patients above 50 years of age with stage I-II hormone receptor positive (HR+) HER2-negative (HER2-) breast cancer and a low-risk 70-gene signature (MammaPrint®). However, the contribution of the 70-gene signature in high-risk subgroups by nodal involvement, grade 3 or larger tumors, has not been reported, which may complicate clinical decision making for these patients. PATIENTS AND METHODS: Patients above 50 years enrolled in the MINDACT trial with primary stage I-II HR + HER2- breast cancer and a clinical high/genomic low-risk were selected for this exploratory analysis. In the MINDACT trial, these patients were randomized at enrollment based on their risk assessment method for the decision to receive ACT or not. Eight-year distant metastasis free survival (DMFS) was the primary endpoint. RESULTS: Median follow-up was 8.7 years. Of the 868 clinical high/genomic low-risk MINDACT patients, 490 (56.5%) patients had tumors larger than 2 cm, 232 (26.7%) had grade 3 tumors and 406 (46.8%) had 1-3 involved lymph nodes. 8-year DMFS in the no ACT group was 87.9% (95%CI: 82.9-91.6%) in patients with tumors larger than 2 cm; 91.3% (95%CI: 84.0-95.4%) with grade 3 tumors and 89.6% (95%CI: 84.2-93.3%) with nodal involvement. Absolute 8-year DMFS benefit for ACT versus no ACT was 1.2%; -2.2% and 0.7% respectively. CONCLUSIONS: This exploratory subgroup analysis of the MINDACT trial confirms the prognostic performance of the 70-gene signature in patients with high-risk features such as larger tumors, grade 3 tumors and 1-3 involved lymph nodes.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Gielen RCAM, Poncet C, van 't Veer LJ, et al. 70-gene signature MammaPrint for early-stage HR-positive, HER2-negative breast cancer: Outcome in the MINDACT trial for key clinical-pathological high-risk subgroups. Eur J Cancer. 2026. PMID: 42762561. doi:10.1016/j.ejca.2026.117044

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。